Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2, and Libtayo, whose sales reached $285 million in Q1 2025.
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
US FDA approves Regeneron's blood cancer therapy
The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, providing another treatment option for patients with a recurring and common form of blood cancer.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Regeneron Pharmaceuticals, Inc. faces declining Eylea sales due to competition from Roche's Vabysmo and biosimilars like Amgen's Pavblu, but Dupixent's strong growth and new indications provide a robust near-term revenue driver. Libtayo and the oncology pipeline offer potential, but face tough competition and are unlikely to become blockbuster catalysts in the short term. The company's move into obesity drugs is a favorable development, with considerable potential from its experimental drug Trevogrumab, which shows promise in early trial data.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Christopher R. Fenimore - Executive VP of Finance & CFO Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great.
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
REGN Stock Undervalued At $500?
Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment in conjunction with Sanofi, during a late-stage clinical trial. One of the two trials did not achieve its primary endpoint, which is a significant setback considering that itepekimab was anticipated to become a blockbuster drug, with peak sales projections from Sanofi estimated between $2 billion and $6 billion.
Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.
